Coverage of our peer-reviewed research in the healthcare and mainstream press.
A Pharmacy Times article, “Childhood Vaccinations: It’s Not About Manufacturer Profit,” discussed the findings of a study in the January 2017 issue of The American Journal of Managed Care® (AJMC®). The research found that vaccinating children born in the United States in 2009 will generate $184 billion in net social value and save 1.2 million quality-adjusted life-years. As the Pharmacy Times article emphasized, vaccine manufacturers “accrued 2% of total value in the form of gross profits” while “society as a whole retained the other 98%.”
A recent commentary in Peritoneal Dialysis, “Racial Disparity in Access to Home Therapies — We Have the Power to Change,” cited an AJMC® study that could help explain the “nationwide underrepresentation of African American/Hispanic patients on home hemodialysis.” The research, titled “Effects of Physician Payment Reform on Provision of Home Dialysis,” found that dialysis in centers has become more lucrative than home dialysis.
AJMC® newsroom content was included in 2 of the National Pharmaceutical Council’s daily e-newsletters this week. On Monday, it mentioned “ICER’s Updated Value Framework Open for Public Comment,” an article by Surabhi Dangi-Garimella, PhD, about the framework recently released by the Institute for Clinical and Economic Research, as well as “5 Key Highlights From the AcademyHealth National Health Policy Conference,” also written by Dangi-Garimella. On Thursday, the newsletter featured an AJMC® video interview in which Mark McClellan, MD, PhD, discussed how to reduce administrative burdens in the move to value-based care.
ERISA Industry Committee Sues Minnesota Over PBM Law
January 3rd 2025The Employee Retirement Income Security Act (ERISA) Industry Committee filed a legal challenge against the Minnesota Department of Commerce, arguing that Minnesota’s Pharmacy Benefit Manager (PBM) Licensure and Regulation Act illegally interfered with employer-sponsored health plans by restricting plan design options and increasing costs.
Read More
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More